An­oth­er win for Novo's semaglu­tide? Physi­cians pre­fer it most in the emerg­ing field of NASH treat­ments, sur­vey finds

As fat­ty liv­er dis­ease gets a new name, will it al­so fi­nal­ly get ap­proved drug treat­ments?

That’s what health­care pro­fes­sion­als are hop­ing for as non­al­co­holic fat­ty liv­er dis­ease (NAFLD) be­comes meta­bol­ic dys­func­tion-as­so­ci­at­ed steatot­ic liv­er dis­ease (MASLD), and non­al­co­holic steato­hep­ati­tis (NASH) be­comes meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH). The name changes, aimed at get­ting rid of stig­ma­tiz­ing lan­guage like “fat­ty liv­er,” are set to be ful­ly rolled out lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER